Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-on hydrochlorothiazide to olmesartan medoxomil + amlodipine in uncontrolled moderate to severe hypertension
2008-003535-20Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydrochlorothiazide, olmesartan and amlodipine in essential hypertension (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in trough seated diastolic blood pressure at Week 16. Started Mar 2009; status: completed.
02
Drugs
hydrochlorothiazideolmesartanamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2008-003535-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003535-20.